fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Sage Therapeutics announces a strategic reorganisation

Written by | 2 Nov 2024

Sage Therapeutics, Inc. announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae in postpartum depression and focus pipeline development efforts ahead of… read more.

FDA approves Zurzuvae, the first and only oral treatment for postpartum depression, and issues a complete response letter for major depressive disorder – Sage Therapeutics + Biogen

Written by | 9 Aug 2023

Sage Therapeutics, Inc .and Biogen Inc. announced the FDA approved Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD). Zurzuvae is the first and only oral, once-daily,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.